Burning mouth syndrome (BMS) presents as a chronic burning, scalding, or tingling sensation affecting the tongue, lips, palate, or a broader area of the mouth, occurring without a visible lesion or identifiable local cause. The condition is thought to arise from dysfunction in the small nerve fibers that carry sensation from the oral mucosa. A newly published real-world study examined whether a topical (intraoral swish-and-spit) formulation of the nerve-pain medication pregabalin — a compounded preparation, as no such product is commercially available or FDA-approved for this indication — could reduce burning symptoms. ([PMID 42512841])
Key Points
- BMS is a form of neuropathic pain — nerve signaling gone awry, not tissue damage — usually diagnosed after ruling out other causes of oral burning.
- A 2026 real-world study of 100 patients found topical pregabalin (a compounded intraoral swish-and-spit solution) reduced median pain from 8/10 to 5/10 over 3 months, with 46% of patients reaching a ≥30% reduction in pain ([PMID 42512841]).
- No serious adverse events were reported in the study, which is notable given that oral (systemic) pregabalin commonly causes dizziness and sedation; however, the study did not include pharmacokinetic or serum-level data, so it cannot confirm whether systemic drug exposure was actually reduced.
- The study was uncontrolled (no placebo group), followed patients for only 3 months, and did not report baseline patient characteristics (e.g., primary vs. secondary BMS, prior treatment history, symptom duration), attrition/dropout rate, or the full distribution of responses beyond the ≥30% threshold. These gaps limit how the results should be interpreted.
- Topical pregabalin requires compounding and is not a commercially available or FDA-approved formulation. Per the source study, it may merit consideration in medically complex patients with tolerability concerns regarding systemic medications, pending further evidence from controlled trials.
What is burning mouth syndrome?
BMS is a chronic burning, tingling, or scalded sensation affecting the tongue, lips, palate, or a broader area of the mouth, occurring in the absence of any visible lesion or identifiable local cause. It is classified as a neuropathic pain condition — evidence points to dysfunction of small sensory nerve fibers in the oral mucosa, and some studies have found abnormalities in taste-nerve (chorda tympani) function in affected patients. The exact mechanism is still being defined.
How is it diagnosed?
BMS is a diagnosis of exclusion. Per the International Classification of Headache Disorders (ICHD-3), the operational diagnostic criteria require daily recurrent oral burning for more than 2 hours per day, present for more than 3 months, without an evident causative lesion on clinical examination.
Before the label is applied, the dentist or physician needs to rule out other conditions that can cause similar burning, including:
- Local irritants: ill-fitting dentures, allergic reactions to dental materials, oral candidiasis (thrush)
- Systemic conditions: vitamin B12, iron, or folate deficiency, diabetes, thyroid dysfunction, dry mouth (xerostomia) from medications or Sjögren’s syndrome
- Other oral mucosal disease
A thorough case history covers not just the burning itself but associated symptoms like taste changes (often described as metallic), dry mouth sensation, and psychological factors such as anxiety or interpersonal stress, since these can influence how pain is experienced and managed. When taste dysfunction is present, standardized taste testing may be recommended. Once these other causes are excluded and the burning pattern fits the diagnostic criteria above, a diagnosis of BMS is made.
Which treatment is right for me?
Treatment for BMS is individualized, and the strength of evidence varies considerably across options.
| Option | What the evidence shows | Best suited to |
|---|---|---|
| Clonazepam troche (topical, dissolved in mouth) | Tested in double-blind, placebo-controlled trials with demonstrated efficacy | First-line topical option with the strongest trial evidence |
| Topical pregabalin (compounded swish-and-spit; not a commercially available or FDA-approved formulation) | Real-world study (n=100, uncontrolled): median pain 8→5 out of 10 at 3 months, 46% with ≥30% reduction, no serious adverse events reported; baseline patient characteristics, attrition, and full response distribution not reported ([PMID 42512841]) | Medically complex patients with tolerability concerns regarding systemic medications; requires compounding pharmacy access; further controlled trials needed |
| Systemic tricyclics (amitriptyline, nortriptyline) | Based on expert opinion and clinical practice; not yet tested in double-blind placebo-controlled trials | Patients who tolerate systemic medication and need broader neuropathic pain coverage |
| Systemic pregabalin (oral, 50–150 mg/day) | Based on expert opinion and clinical practice; not yet tested in double-blind placebo-controlled trials | Similar profile to other gabapentinoid/anticonvulsant options |
| Topical capsaicin cream (0.025%) | Based on expert opinion and clinical practice; not yet tested in double-blind placebo-controlled trials | Patients preferring a topical, non-systemic approach |
| Cognitive behavioral therapy (CBT) | Recommended specifically for patients showing maladaptive coping or interpersonal distress | Adjunct for patients with a significant psychological component to their pain |
A general principle in BMS management: any therapy should be given an adequate trial — at least one month, if tolerated — before concluding it isn’t working and moving to another option.
What the new study adds — and its limits
The study tracked 100 patients using a compounded pregabalin solution as an intraoral rinse rather than a swallowed tablet. The rationale for topical delivery is to act locally on oral nerve fibers while potentially limiting the amount of drug reaching the systemic circulation, where pregabalin’s more common side effects (dizziness, sedation, weight gain) are thought to originate. The study did not report pharmacokinetic or serum-level data, so this reduced-systemic-exposure rationale is an untested hypothesis rather than a confirmed finding; the absence of serious adverse events in an unblinded, uncontrolled cohort could equally reflect under-monitoring, patient-reported outcome bias, or the short follow-up period. Median pain scores dropped from 8/10 to 5/10 over three months, and 46% of patients reached a ≥30% reduction in pain. No serious adverse events were reported ([PMID 42512841]).
The available study summary also does not report several details relevant to interpreting these results: whether participants were treatment-naïve or had already failed other therapies, whether BMS was primary or secondary, symptom duration at enrollment, the study’s attrition or dropout rate, or the distribution of responses beyond the ≥30% threshold (for example, how many patients had no response or worsened). These gaps limit the conclusions that can be drawn about the generalizability and durability of the reported effect.
In addition, this was a real-world, uncontrolled study — there was no placebo group for comparison, and follow-up stopped at 3 months. Pain conditions like BMS are known to fluctuate and respond partly to attention and expectation, so a portion of the improvement seen here cannot be separated from those effects without a controlled trial. The authors themselves note that controlled studies comparing topical pregabalin against standard systemic agents are still needed before it can be considered an established treatment.
When to see a specialist
Consider an orofacial pain evaluation if oral burning has lasted more than a few weeks, your dentist and physician have ruled out infections, deficiencies, and denture-related irritation, and standard reassurance or over-the-counter remedies haven’t helped. A specialist can confirm the diagnosis, screen for the underlying local and systemic causes noted above, and structure a stepwise trial of the therapies with the best supporting evidence.
For referring providers
Topical pregabalin, compounded as an intraoral swish-and-spit solution, is not a commercially available or FDA-approved formulation for BMS and requires access to a compounding pharmacy. It represents an emerging option supported so far by one uncontrolled real-world study (n=100) showing median pain reduction from 8/10 to 5/10 at 3 months, 46% achieving ≥30% reduction, and no serious adverse events reported ([PMID 42512841]); the study did not report baseline patient characteristics, attrition, or the full distribution of treatment responses. This adds to a treatment landscape where only topical clonazepam has double-blind, placebo-controlled support; systemic tricyclics, systemic pregabalin, and topical capsaicin remain expert-opinion-based (Patton et al., 2007; Zakrzewska and Buchanan, 2016). Given the absence of a control arm, short follow-up, and unreported baseline characteristics in the pregabalin study, patient counseling should frame it as investigational rather than established. Per the source study, it may merit consideration as a discussion point for medically complex patients with tolerability concerns regarding systemic neuropathic pain agents, pending further evidence — and any such discussion should include the cost and access implications of compounding. Standard BMS workup — ruling out candidiasis, hematinic deficiencies, xerostomia, and denture-related irritation — remains a prerequisite before initiating any BMS-directed therapy.
Patients experiencing persistent oral burning are welcome to schedule an evaluation with our practice to review diagnosis and treatment options.
References
- Topical Pregabalin in Burning Mouth Syndrome: A Real-World Study of Peripheral Neuromodulation. [PMID 42512841]
- Patton LL, et al. (2007). Referenced in: Clinical Cases in Orofacial Pain — BMS treatment options and management.
- Zakrzewska J, Buchanan JAG (2016). Referenced in: Clinical Cases in Orofacial Pain — BMS treatment options and management.
- Eliav E, Kamran B, Schaham R, et al. (2007). Evidence of chorda tympani dysfunction in patients with burning mouth syndrome. J Am Dent Assoc.
